FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 701–800 of 1,002
Motobayashi, H., Kitahata, Y., Okada, K., Miyazawa, M., Ueno, M., Hayami, S., Miyamoto, A., Shimizu, A., Sato, M., Yoshimura, T., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05594-1 · Cited by 23
“…plus nab-paclitaxel (GEM plus nab-PTX) and FOLFIRINOX are the standard chemotherapy regimens recommended for first-line treatment of locally advanced and metastatic pancreatic cancer, and these regimens have provided favorable survival benefits (Conroy et al. 2011, 2018; Von Hoff et al. 2013).”
BackgroundPecoraro, C., Carbone, D., Scianò, F., Terrana, F., Xu, G., Bergonzini, C., Roeten, M. S. F., Cascioferro, S., Cirrincione, G., Diana, P., et al. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2385557 · Cited by 20
“…treatment for locally-advanced or metastatic PDac patients consists of cytotoxic chemotherapy, primarily FOlFiRiNOX and gemcitabine-based regimens [7–9]. indeed promising immunotherapeutic approaches that have shown success in various solid tumours, such as melanoma or renal cell carcinoma, are…”
Galvano, A., Castiglia, M., Rizzo, S., Silvestris, N., Brunetti, O., Vaccaro, G., Gristina, V., Barraco, N., Bono, M., Guercio, G., et al. (2020) · Cancers · doi:10.3390/cancers12030534 · Cited by 22
Guo, J., Zhang, P., Zhou, L., You, L., Liu, Q., Zhang, Z., Sun, B., Liang, Z.-Y., Lü, J., Yuan, D., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102767 · Cited by 24
Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer
Cazacu, I. M., Singh, B. S., Săftoiu, A., & Bhutani, M. S. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-00767-1 · Cited by 20
Preoperative Chemotherapy for Pancreatic Cancer Improves Survival and R0 Rate Even in Early Stage I
Vega, E. A., Kutlu, O. C., Salehi, O., James, D. M., Alarcon, S. V., Herrick, B. B., Krishnan, S., Kozyreva, O. N., & Conrad, C. H. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04601-x · Cited by 20
Franco, F., Cámara, J. C., Martin-Valades, J. I., López‐Alfonso, A., Marrupe, D., Gutiérrez-Abad, D., Martínez-Amores, B., León, A., Juez, I., Pérez, M., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02473-w · Cited by 20
Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers
Kaczor‐Urbanowicz, K. E., Cheng, J. C., King, J. C., Sedarat, A., Pandol, S. J., Farrell, J. J., Wong, D. T., & Kim, Y. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001662 · Cited by 26
“011).(107) Quite the contrary, Allenson et al(62) and Singh et al(104) were unable to determine a significant difference in survival when comparing patients with cfDNA mutant KRAS and those with cfDNA wild-type KRAS.”
ResultSrivastava, S., Widmann, S., Ho, C., Nguyen, D., Nguyen, A., Premaratne, A., Gustafsson, J.-Α., & Lin, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249622 · Cited by 21
“The combination treatment of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has a longer overall survival than gemcitabine alone in patients with metastatic pancreatic cancer, but overall efficacy, toxicity, and development of resistance remain significant challenges [2,3].”
BackgroundGender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
Kim, J., Ji, E., Jung, K., Jung, K., Park, J., Lee, J.-C., Kim, J. W., Hwang, J., & Kim, J. W. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020083 · Cited by 23
“Furthermore, FOLFIRINOX has shown excellent efficacy in not only palliative but also adjuvant settings [5], and this regimen has been used as the neoadjuvant chemotherapy in several phase III clinical trials [6].”
MethodAdvances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades
Taboada, Á. G. M., Lozano, P., Martín-Román, L., Alfonso, P. G., Martín, A. J. M., Rodriguez, J. A. B., & Asencio, J. M. (2021) · Annals of Hepato-Biliary-Pancreatic Surgery · doi:10.14701/ahbps.2021.25.2.179 · Cited by 20
“This has led to a greater emphasis on the use of neoadjuvant therapy for patients without evidence of metastatic disease.(9,29,30) The neoadjuvant approach, gives the chance of receive CT treatment in most of medically fit patients.”
BackgroundMetabolic Alterations as a Signpost to Early Pancreatic Cancer
Khalaf, N. I., & Wolpin, B. M. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.028 · Cited by 21
Modelling and breaking down the biophysical barriers to drug delivery in pancreatic cancer
Kpeglo, D., Haddrick, M., Knowles, M. A., Evans, S. D., & Peyman, S. A. (2024) · Lab on a Chip · doi:10.1039/d3lc00660c · Cited by 22
Ghadimi, M. B., Pelzer, U., Besselink, M. G., Siveke, J. T., Telgmann, R., Braren, R., Wilmink, H. W., Crede, M., König, A. O., Koenig, U., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13573-7 · Cited by 19
van Roessel, S. R., Strijker, M., Steyerberg, E. W., Groen, J. V., Mieog, J. S. D., Groot, V. P., He, J. P., Pastena, M. D., Marchegiani, G., Bassi, C., et al. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.12.023 · Cited by 23
Taı̈eb, J., & Abdallah, R. (2019) · ESMO Open · doi:10.1136/esmoopen-2020-000818 · Cited by 19
Tanaka, K., Nakamura, T., Asano, T., Nakanishi, Y., Noji, T., Tsuchikawa, T., Okamura, K., Shichinohe, T., & Hirano, S. (2020) · Pancreatology · doi:10.1016/j.pan.2020.08.014 · Cited by 19
Luu, A. M., Braumann, C., Belyaev, O., Janot-Matuschek, M. S., Rudolf, H., Praktiknjo, M., & Uhl, W. H. (2020) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2020.12.006 · Cited by 25
Frigerio, I. M., Paiella, S., Barbi, E., Bianco, R., Boz, G., Butturini, G., Cantore, M., Cardarelli, N., D’Onofrio, M., Fiorentini, G., et al. (2021) · Pancreatology · doi:10.1016/j.pan.2021.06.005 · Cited by 19
van der Sijde, F., Azmani, Z., Besselink, M. G., Bonsing, B. A., de Groot, J. W. B., Koerkamp, B. G., Haberkorn, B. C. M., Homs, M. Y. V., van IJcken, W. F. J., Janssen, Q. P., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211033704 · Cited by 21
The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection
Xu, Y., Wang, Y., Höti, N., Clark, D. J., Chen, S., & Zhang, H. (2021) · Mass Spectrometry Reviews · doi:10.1002/mas.21748 · Cited by 26
Targeting the Endocannabinoidome in Pancreatic Cancer
Falasca, V., & Falasca, M. (2022) · Biomolecules · doi:10.3390/biom12020320 · Cited by 21
“However, even when used in combination with other anticancer agents, therapy has shown only minimal improvements in survival, at the cost of substantial toxicity and side effects [55].”
BackgroundHill, C., Rosati, L. M., Wang, H., Tsai, H., He, J. P., Hacker‐Prietz, A., Laheru, D. A., Zheng, L., Sehgal, S., Bernard, V., et al. (2022) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.02.009 · Cited by 21
Chen, P., Zeng, Z., Wang, J., Cao, W., Song, C., Lei, S., Li, Y., & Ren, Z. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01008-2 · Cited by 19
“Although surgical resection combined with chemotherapy is an effective treatment for PC, only a small number of patients are eligible for surgical resection [20].”
BackgroundThe impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer
Guenther, M., Boeck, S. H., Heinemann, V., Werner, J., Engel, J., & Ormanns, S. (2022) · International Journal of Cancer · doi:10.1002/ijc.34044 · Cited by 19
“In PRODIGE-24, only 26 patients had stage I disease (UICC 7th edition, 2010), rendering a comparative analysis of this subgroup impossible.(6) Scarce retrospective data, relying on OS as surrogate marker only, indicated a beneficial effect of adjuvant therapy also in stage I PDAC.”
BackgroundMethodIDO1 Is a Therapeutic Target for Pancreatic Cancer–Associated Depression
Hue, J. J., Graor, H. J., Zarei, M., Katayama, E., Ji, K., Hajihassani, O., Loftus, A. W., Gohar, A. V., & Winter, J. M. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0055 · Cited by 18
Reprogramming of pancreatic adenocarcinoma immunosurveillance by a microbial probiotic siderophore
Chaib, M., Hafeez, B. B., Mandil, H., Daria, D., Pingili, A. K., Kumari, S., Sikander, M., Kashyap, V. K., Chen, G., Anning, E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04102-4 · Cited by 24
Pancreatic Organoids: A Frontier Method for Investigating Pancreatic-Related Diseases
Liu, Y., Li, N., & Zhu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044027 · Cited by 23
“FOLFIRINOX is an important component of adjuvant chemotherapy in advanced cancer and improves overall survival compared with that observed with gemcitabine monotherapy [73].”
BackgroundShen, X., Wang, X., Zheng, Z., Chen, Y., Tan, C., Liu, X., & Ke, N. (2023) · Cancer Medicine · doi:10.1002/cam4.5779 · Cited by 20
Li, Y., Wang, X., Ding, B., He, C., Zhang, C., Li, J., Wang, H., Li, Z., Wang, G., Wang, Y., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142690 · Cited by 19
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer
Guenther, M., Surendran, S. A., Haas, M., Heinemann, V., von Bergwelt‐Baildon, M., Engel, J., Werner, J., Boeck, S. H., & Ormanns, S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02295-x · Cited by 19
“In the operable situation, the introduction of routine adjuvant chemotherapy increased disease-free survival times (DFS) and overall survival times (OS) significantly; first established with adjuvant gemcitabine [3] which has been partially replaced by more active regimens like FOLFIRINOX only in clinically fit patien…”
BackgroundResultLi, D., Peng, Q., Wang, L., Cai, W., Liang, M., Liu, S., Ma, X., & Zhao, X. (2023) · European Radiology · doi:10.1007/s00330-023-09980-8 · Cited by 21
“Curative R0 resection (microscopically margin-negative) followed by adjuvant chemotherapy, the mainstay of therapy, may allow patients to achieve long-term survival [3, 4].”
Klassen, P. N., Baracos, V. E., Ghosh, S., Martin, L., Sawyer, M. B., & Mazurak, V. C. (2023) · Cancers · doi:10.3390/cancers15174368 · Cited by 19
“FOLFIRINOX is used as both a neoadjuvant and adjuvant therapy for resectable pancreatic tumours [40].”
BackgroundThe Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
Tran, L. C., Özdemir, B. C., & Berger, M. D. (2023) · Pharmaceuticals · doi:10.3390/ph16101411 · Cited by 20
“Pancreatic resection, followed by adjuvant chemotherapy, is currently the only curative intended option to achieve long-term survival [2].”
BackgroundYao, Z., Qi, C., Zhang, F., Yao, H., Wang, C., Cao, X., Yao, C., Wang, Z., Qi, M., Yao, C., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.10.024 · Cited by 20
Rashid, Z., Munir, M. M., Woldesenbet, S., Khan, M. M. M., Khalil, M., Endo, Y., Tsilimigras, D. I., Dillhoff, M., Ejaz, A. M., & Pawlik, T. M. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27571 · Cited by 20
Iqbal, H., Inam‐Ur‐Raheem, M., Munir, S., Rabail, R., Kafeel, S., Shahid, A., Mousavi Khaneghah, A., & Aadil, R. M. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3869 · Cited by 19
Gayibov, E., Sychra, T., Spálenková, A., Souček, P., & Oliverius, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117750 · Cited by 27
Imaging and Management of Pancreatic Cancer
Kobi, M., Veillette, G. R., Narurkar, R., Sadowsky, D., Paroder, V., Shilagani, C., Gilet, A. G., & Flusberg, M. (2019) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2019.12.003 · Cited by 18
Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head
Haines, M., Chua, T. C., Jamieson, N. B., Mittal, A., Gill, A. J., & Samra, J. S. (2020) · Pancreas · doi:10.1097/mpa.0000000000001551 · Cited by 19
“1 months with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).(6) Mirroring the improvement in the medical management of pancreatic cancer, pancreatoduodenectomy (PD), which was previously regarded a highly morbid procedure with early experiences documenting mortality rates of 15%,(7) has now fallen…”
BackgroundNassour, I., Adam, M. A., Kowalsky, S. J., Masri, S. S. A., Bahary, N., Singhi, A. D., Lee, K., Zureikat, A. H., & Paniccia, A. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26267 · Cited by 19
Invadopodia: A potential target for pancreatic cancer therapy
Luo, Y., Hu, J., Liu, Y., Li, L., Li, Y., Sun, B., & Kong, R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103236 · Cited by 22
Deng, A., Wang, C., Cohen, S. J., Winter, J. M., Posey, J. A., Yeo, C. J., & Mallick, A. B. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.004 · Cited by 19
Ay, S., Atçı, M. M., Arıkan, R., Dülgar, Ö., Özyükseler, D. T., Paksoy, N., Doğan, İ., Öztosun, B., Taştekin, D., Ustaalıoğlu, B. B. Ö., et al. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2026125 · Cited by 20
“[24] compared FFX and gemcitabine treatment in 493 patients.”
Machine-Learning-Based Bibliometric Analysis of Pancreatic Cancer Research Over the Past 25 Years
Wang, K., & Herr, I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832385 · Cited by 23
“…from the French-Canadian Uni-Cancer GI PRODIGE 24/ CCTGPA.6 trial demonstrated that a modi fi ed FOLFIRINOX chemotherapy regimen improved the survival time to 54.4 months in patients with macroscopically resected pancreatic cancer compared to 35 months in the gemcitabine monotherapy group (5, 7).”
BackgroundInfluentialPrognostic Factors of Acinar Cell Carcinomas
Egal, A., Cros, J. F., Svrcek, M., Chiche, L., Belleannée, G., Poizat, F., Jouffret, L., Maire, F., de Mestier, L., & Hammel, P. R. (2019) · Pancreas · doi:10.1097/mpa.0000000000001440 · Cited by 19
Self-citationThe potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer
Bakadlag, R., Jandaghi, P., Hoheisel, J. D., & Riazalhosseini, Y. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1606904 · Cited by 21
Li, X., Chen, Y., Qiao, G., Ni, J., Chen, T., Wang, Y., Wu, C., Zhang, Q., Ma, T., Gao, S., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217658 · Cited by 20
Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies
du Toit‐Thompson, T., Leck, L. Y. W., Gillson, J., Pavlakis, N., Gill, A. J., Samra, J. S., Mittal, A., & Sahni, S. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115647 · Cited by 22
Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes
Alese, O. B., Jiang, R., Shaib, W. L., Wu, C., Akce, M., Gaines, T. M., Ni, L., Behera, M., & El‐Rayes, B. F. (2020) · Pancreas · doi:10.1097/mpa.0000000000001502 · Cited by 22
Park, H., Jin, R. U., Wang‐Gillam, A., Suresh, R., Rigden, C. E., Amin, M. A., Tan, B. R., Pedersen, K. S., Lim, K., Trikalinos, N. A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2020 · Cited by 18
Wolfe, A. R., Robb, R. N., Hegazi, A., Abushahin, L. I., Yang, L., Shyu, D.-L., Trevino, J. G., Cruz‐Monserrate, Z., Jacob, J. R., Palanichamy, K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1422 · Cited by 18
Safi, S. A., Fluegen, G., Rehders, A., Häberle, L., Fung, S., Keitel, V., Krieg, A. H., Knoefel, W. T., & Lehwald, N. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01961-5 · Cited by 18
Hossain, M. A., Lin, Y., Driscoll, G., Li, J., McMahon, A., Matos, J., Zhao, H., Tsuchimoto, D., Nakabeppu, Y., Zhao, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738502 · Cited by 18
Woeste, M. R., Wilson, K. D., Kruse, E., Weiss, M. J., Christein, J. D., White, R. R., & Martin, R. C. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.817220 · Cited by 20
“per standard of care and each institutions management (23).”
BackgroundTumour microenvironment and heterotypic interactions in pancreatic cancer
Velasco, R. M., García, A. G., Sánchez, P. J., Sellart, I. M., & Lobo, V. J. S.-A. (2022) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-022-00875-8 · Cited by 19
“However, only a small fraction of patients responds to these chemotherapies [20].”
BackgroundShoucair, S., Chen, J., Martinson, J. R., Habib, J. R., Kinny‐Köster, B., Pu, N., van Oosten, A. F., Javed, A. A., Shin, E. J., Ali, S. Z., et al. (2022) · JAMA Surgery · doi:10.1001/jamasurg.2022.1362 · Cited by 19
The molecular landscape of pancreatic ductal adenocarcinoma
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · Pancreatology · doi:10.1016/j.pan.2022.07.010 · Cited by 24
Tomimaru, Y., Eguchi, H., Shimomura, Y., Kitamura, T., Inoue, Y., Nagakawa, Y., Ohba, A., Onoe, S., Unno, M., Hashimoto, D., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01988-7 · Cited by 22
Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma—A Critical Review of Randomised Trials
Ejlsmark, M. W., Schytte, T., Bernchou, U., Bahij, R., Weber, B., Mortensen, M. B., & Pfeiffer, P. (2023) · Current Oncology · doi:10.3390/curroncol30070499 · Cited by 21
“Still, the introduction of modern combination chemotherapy has significantly prolonged the median overall survival to 9–11 months, with tolerable toxicity [20,21].”
BackgroundLiquid biopsy analysis of lipometabolic exosomes in pancreatic cancer
Guo, W., Ying, P., Ma, R., Jing, Z., Ma, G., Long, J., Li, G., & Liu, Z. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.07.006 · Cited by 20
Long non-coding RNAs and pancreatic cancer: A multifaceted view
Wang, B., Chang, Y., Qie, Y., & Dang, S.-C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115601 · Cited by 20
Dallavalle, S., Campagnoli, G., Pastena, P., Martinino, A., Schiliró, D., & Giovinazzo, F. (2024) · Medicina · doi:10.3390/medicina60071070 · Cited by 22
“NAT has emerged as a promising strategy to address a crucial aspect of this therapeutic approach: enhancing resectability and potentially eradicating micrometastases through pre-operative therapy in patients with upfront resectable PDAC [40].”
BackgroundTaniuchi, K., Furihata, M., Naganuma, S., Sakaguchi, M., & Saibara, T. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217920 · Cited by 18
Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?
Fenocchio, E., Filippi, R., Lombardi, P., Quarà, V., Milanesio, M. C., Aimar, G., Leone, F., & Aglietta, M. (2019) · Cancers · doi:10.3390/cancers11101547 · Cited by 18
Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma
da Costa, W. L., Cao, H. S. T., & Massarweh, N. N. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0562 · Cited by 18
Begg, S. K. S., Birnbaum, D. J., Clark, J. W., Mino-Kenudson, M. A., Wellner, U. F., Schilling, O., Lillemoe, K. D., Warshaw, A. L., Castillo, C. F. F.-D., & Liss, A. S. (2020) · Anticancer Research · doi:10.21873/anticanres.14355 · Cited by 18
Appraisal of 5‐year recurrence‐free survival after surgery in pancreatic ductal adenocarcinoma
Yoon, S. J., Shin, S. H., Yoon, S. K., Jung, J. H., You, Y., Han, I. W., Choi, D. W., & Heo, J. S. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.815 · Cited by 18
Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer
Rocha, F. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09367-9 · Cited by 20
Tang, N., Xu, S., Song, T., Qiu, Y., He, J., & Fu, X. (2021) · Cell Proliferation · doi:10.1111/cpr.13031 · Cited by 19
Fromer, M. W., Hawthorne, J. L., Philips, P., Egger, M. E., Scoggins, C. R., McMasters, K. M., & Martin, R. C. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10174-z · Cited by 18
de Jong, E. J. M., Janssen, Q. P., Simons, T. F. A., Besselink, M. G., Bonsing, B. A., Bouwense, S. A. W., Geurts, S. M. E., Homs, M. Y. V., de Meijer, V. E., Tjan‐Heijnen, V. C. G., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33916 · Cited by 17
“003).(11) This evident survival advantage came at the cost of increased chemotherapy-related adverse events in patients treated with modified FOLFIRINOX (mFOLFIRINOX).”
BackgroundNie, R., Zou, X., Yuan, S., Chen, Y.-B., Chen, S., Chen, Y.-M., Chen, G., Chen, X., Luo, T., Li, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06910-5 · Cited by 22
Amintas, S., Fernandez, B., Chauvet, A., Chiche, L., Laurent, C., Belleannée, G., Marty, M., Buscail, E., & Dabernat, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-07004-x · Cited by 17
Liu, Y., Kaur, S., Huang, Y., Fahrmann, J. F., Rinaudo, J. A., Hanash, S. M., Batra, S. K., Singhi, A. D., Brand, R. E., Maitra, A., et al. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0161 · Cited by 17
Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
Mendes, I., & Vale, N. (2024) · Biomedicines · doi:10.3390/biomedicines12010227 · Cited by 21
“The latest advances in chemotherapy treatments have enhanced the results of resectable PDAC [5] but are still insufficient.”
BackgroundWiktorin, H. G., Aydin, E., Kiffin, R., Vilhav, C., Fagman, J. B., Kaya, M., Paul, S., Westman, B., Bratlie, S. O., Naredi, P. L. J., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0447 · Cited by 19
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Chambers, C. R., Watakul, S., Schofield, P., Howell, A. E., Zhu, J., Tran, A. M. H., Kuepper, N., Reed, D. A., Murphy, K. J., Channon, L. M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq4416 · Cited by 19
Dickerson, L., Gittens, J., Brunning, C., Jackson, R., Schmid, M. C., Mielgo, A., Palmer, D. H., Halloran, C. M., & Ghaneh, P. (2025) · BJS Open · doi:10.1093/bjsopen/zrae172 · Cited by 23
“In adjuvant trials, resection margin status and lymphatic involvement are correlated with OS 4,5 .”
Pietrantonio, F., Morano, F., Niger, M., Corallo, S., Antista, M., Raimondi, A., Prisciandaro, M., Pagani, F., Prinzi, N., Nichetti, F., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.004 · Cited by 17
Chawla, A., Qadan, M., Castillo, C. F. F.-D., Wo, J. Y.-L., Allen, J. N., Clark, J. W., Murphy, J. E., Catalano, O. A., Ryan, D. P., Ting, D. T., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004585 · Cited by 17
Jones, O. Z., Cheng, X., Murthy, S. R. K., Ly, L., Zhuang, T., Basadonna, G. P., Keidar, M., & Canady, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-88451-w · Cited by 17
The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids
Low, R. R. J., Lim, W., Nguyen, P. M., Lee, B., Christie, M., Burgess, A. W., Gibbs, P., Grimmond, S. M., Hollande, F., & Putoczki, T. L. (2021) · Cancers · doi:10.3390/cancers13194979 · Cited by 20
“5 months improvement in median OS), both improve OS when compared with gemcitabine alone [31,32].”
BackgroundWon, E.-J., Park, H., Yoon, T., & Cho, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010137 · Cited by 19
“4 months among patients with resected pancreatic cancer [4].”
BackgroundBlaauboer, A., van Koetsveld, P. M., Mustafa, D. A. M., Dumas, J., Dogan, F., van Zwienen, S., van Eijck, C. H. J., & Hofland, L. J. (2022) · Biomedicines · doi:10.3390/biomedicines10030517 · Cited by 18
“Despite the increased use of more effective chemotherapeutic combinations, such as FOLFIRINOX or gemcitabine with either nab-paclitaxel or capecitabine, resistance is still a major impediment to the successful treatment of pancreatic cancer [7].”
BackgroundFrom prehab to rehab: Nutritional support for people undergoing pancreatic cancer surgery
Bibby, N., Rajai, A., & O'Reilly, D. A. (2022) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.13040 · Cited by 24
Bryant, J. M., Palm, R. F., Liveringhouse, C. L., Boyer, E., Hodul, P., Malafa, M. P., Denbo, J. W., Kim, D. H., Carballido, E. M., Fleming, J. B., et al. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.101045 · Cited by 21
“Postsurgical hospitalization length, median (d) 7 (4-13)”
BackgroundWeishen, W. A. N. G., Lou, W., Zhiwei, X. U., Haoda, C. H. E. N., Shen, Z., Deng, X., Peng, C., Yingbin, L. I. U., & Shen, B. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.09.011 · Cited by 18
Analysis of the fecal metagenome in long‐term survivors of pancreas cancer
Kharofa, J. R., Haslam, D. B., Wilkinson, R., Weiss, A., Patel, S. H., Wang, K., Esslinger, H. R., Olowokure, O. O., Sohal, D. P. S., Wilson, G. C., et al. (2023) · Cancer · doi:10.1002/cncr.34748 · Cited by 21
Reyes‐Castellanos, G., Hadi, N. A., Gallardo-Arriaga, S., Masoud, R., Garcia, J., Lac, S., Kaoutari, A. E., Gicquel, T., Planque, M., Fendt, S., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106899 · Cited by 17
“Clinically, only 15%–20% of patients are eligible for surgical tumor resection, and most of them will face chemoresistance and relapse at some point during treatment or after cure.(6,7) Moreover, 80–85% of patients present with infiltration of surrounding structures or metastasis at diagnosis,(8,9) for which standard…”
BackgroundSu, Y., Chao, Y., Wang, C., Liao, T., Su, P., Huang, C., Chiang, N., Yu, Y., Tsai, H., Chen, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000495 · Cited by 19
“Upfront resection (UR) followed by adjuvant modi fi ed FOLFIRINOX (mFOLFIRINOX) achieved the best outcome in PDAC with a median overall survival (OS) of 54.4 months [4] .”
InfluentialThe Use of MR-Guided Radiation Therapy for Pancreatic Cancer
Daamen, L. A., Parikh, P. J., & Hall, W. A. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.10.002 · Cited by 17
Sohal, D. P. S., Boutin, R. D., Lenchik, L., Kim, J., Beg, M. S., Wang‐Gillam, A., Wade, J. L., Guthrie, K. A., Chiorean, E. G., Ahmad, S. A., et al. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2023.12.022 · Cited by 17
Schouten, T. J., van Goor, I. W. J. M., Dorland, G. A., Besselink, M. G., Bonsing, B. A., Bosscha, K. P., Brosens, L. A. A., Busch, O. R., Cirkel, G. A., van Dam, R. M., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15070-w · Cited by 20
Wang, Q., Zhang, Z., Wang, Z., Wang, J., Ren, Y., Sun, X., Tian, J., Kang, F., Zhao, X., & Yan, H. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202400485 · Cited by 16
Huang, Y.-H., Zhang, R., Lyu, H., Xiao, S., Guo, D. S., Chen, X., Zhou, C., & Tang, J. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.91832 · Cited by 21
“…with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or nanoliposome irinotecan plus fluorouracil and leucovorin has been proposed in recent years, and patients treated with combination therapy have longer overall survival than those treated with gemcitabine alone [9, 10].”
BackgroundThe trend toward more target therapy in pancreatic ductal adenocarcinoma
Deiana, C., Agostini, M., Brandi, G., & Giovannetti, E. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2357802 · Cited by 19
“…chemotherapy regimen modified FOLFIRINOX (mFOLFIRINOX: fluorouracil, irinotecan, oxaliplatin), associated with overall survival (OS) of 54 months [4] and survival in the locally advanced setting, even with chemotherapy (FOLFIRINOX or gemcitabine plus nab-paclitaxel) and radiation therapy is…”
BackgroundLocal ablation disrupts immune evasion in pancreatic cancer
Musiu, C., Adamo, A., Caligola, S., Agostini, A., Frusteri, C., Lupo, F., Boschi, F., Busato, A., Poffe, O., Anselmi, C., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217327 · Cited by 18
Preclinical Modelling of PDA: Is Organoid the New Black?
D’Agosto, S. L., Andreani, S., Scarpa, A., & Corbo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112766 · Cited by 17
Fornaro, L., Leone, F., Vienot, A., Gardini, A. C., Vivaldi, C., Lièvre, A., Lombardi, P., Luca, E. D., Vernerey, D., Sperti, E., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.08.004 · Cited by 17
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.